Cancer Research Cancer Epigenetics Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, Y.-M.
Right arrow Articles by Kwon, Y.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, Y.-M.
Right arrow Articles by Kwon, Y.-G.
[Cancer Research 60, 5410-5413, October 1, 2000]
© 2000 American Association for Cancer Research

Biochemistry and Biophysics

Endostatin Inhibits Endothelial and Tumor Cellular Invasion by Blocking the Activation and Catalytic Activity of Matrix Metalloproteinase 21

Young-Mi Kim, Jin-Wook Jang, Ok-Hee Lee, Jungheum Yeon, Eu-Yul Choi, Kyu-Won Kim, Seung-Taek Lee and Young-Guen Kwon2

Department of Biochemistry, College of Natural Science, Kangwon University, Chunchon, Kangwon-Do 200-701 [Y-M. K., Y-G. K.]; Institute of Environment and Life Science [Y-M. K., O-H. L., Y-G. K.] and Department of Genetic Engineering, Hallym University, Chunchon, Kangwon-Do 200-702 [E-Y. C.]; Department of Biochemistry, College of Science, and Bioproducts Research Center, Yonsei University, Seoul 120-749 [J-W. J., J. Y., S-T. L.]; and Department of Molecular Biology, Pusan National University, Pusan 609-735 [K-W. K.], Korea

Here we report the inhibition of cellular invasion by a recombinant mouse endostatin and the possible mechanism of the inhibition. Endostatin significantly reduced endothelial as well as tumor cellular invasion into the reconstituted basement membrane in vitro. Gelatin zymographic analysis revealed that the activation of promatrix metalloproteinase-2 (proMMP-2) that was secreted from endothelial cells was blocked upon endostatin treatment. Studies with recombinant MMPs confirmed that endostatin inhibited proMMP-2 activation, mediated by both membrane-type 1 MMP and 4-aminophenylmercuric acetate. Furthermore, enzymatic assays using a peptide substrate demonstrated that endostatin inhibited the catalytic activities of both MMP-2 and membrane-type 1 MMP. Finally, coimmunoprecipitation experiments revealed that endostatin formed a stable complex with proMMP-2. These novel findings would, at least in part, explain the mechanism of the potent antiangiogenic and antitumor activities of endostatin.




This article has been cited by other articles:


Home page
 BloodHome page
H. Shi, Y. Huang, H. Zhou, X. Song, S. Yuan, Y. Fu, and Y. Luo
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Blood, October 15, 2007; 110(8): 2899 - 2906.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
O. Tatar, A. Adam, K. Shinoda, T. Eckert, G. B Scharioth, M. Klein, E. Yoeruek, K. U. Bartz-Schmidt, and S. Grisanti
Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy
Br J Ophthalmol, September 1, 2007; 91(9): 1183 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
D. Ribatti, M. T. Conconi, and G. G. Nussdorfer
Nonclassic Endogenous Novel Regulators of Angiogenesis
Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
B. Schaffhauser, T. Veikkola, K. Strittmatter, H. Antoniadis, K. Alitalo, and G. Christofori
Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice
J. Leukoc. Biol., October 1, 2006; 80(4): 669 - 676.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H.-M. Cho, J. D. Rosenblatt, Y.-S. Kang, M. L. Iruela-Arispe, S. L. Morrison, M. L. Penichet, Y.-G. Kwon, T.-W. Kim, K. A. Webster, H. Nechustan, et al.
Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein
Mol. Cancer Ther., June 1, 2005; 4(6): 956 - 967.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Nyberg, L. Xie, and R. Kalluri
Endogenous Inhibitors of Angiogenesis
Cancer Res., May 15, 2005; 65(10): 3967 - 3979.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. M. Tjin Tham Sjin, R. Satchi-Fainaro, A. E. Birsner, V.M. S. Ramanujam, J. Folkman, and K. Javaherian
A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor Activity
Cancer Res., May 1, 2005; 65(9): 3656 - 3663.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
T. A. Rege, C. Y. Fears, and C. L. Gladson
Endogenous inhibitors of angiogenesis in malignant gliomas: Nature's antiangiogenic therapy
Neuro-oncol, April 1, 2005; 7(2): 106 - 121.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Isayeva, C. Ren, and S. Ponnazhagan
Recombinant Adeno-Associated Virus 2-Mediated Antiangiogenic Prevention in a Mouse Model of Intraperitoneal Ovarian Cancer
Clin. Cancer Res., February 1, 2005; 11(3): 1342 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Rehman and G. C. Jayson
Molecular Imaging of Antiangiogenic Agents
Oncologist, February 1, 2005; 10(2): 92 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Utriainen, R. Sormunen, M. Kettunen, L. S. Carvalhaes, E. Sajanti, L. Eklund, R. Kauppinen, G. T. Kitten, and T. Pihlajaniemi
Structurally altered basement membranes and hydrocephalus in a type XVIII collagen deficient mouse line
Hum. Mol. Genet., September 15, 2004; 13(18): 2089 - 2099.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Kikuchi, S. Menendez, M. Ohori, C. Cordon-Cardo, N. Kasahara, and B. H. Bochner
Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin
Clin. Cancer Res., March 1, 2004; 10(5): 1835 - 1842.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. O. Schmidt, M. Ziu, G. Carrabba, C. Giussani, L. Bello, Y. Sun, K. Schmidt, M. Albert, P. Mcl. Black, and R. S. Carroll
Antiangiogenic Therapy by Local Intracerebral Microinfusion Improves Treatment Efficiency and Survival in an Orthotopic Human Glioblastoma Model
Clin. Cancer Res., February 15, 2004; 10(4): 1255 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Keezer, S. E. Ivie, H. C. Krutzsch, A. Tandle, S. K. Libutti, and D. D. Roberts
Angiogenesis Inhibitors Target the Endothelial Cell Cytoskeleton through Altered Regulation of Heat Shock Protein 27 and Cofilin
Cancer Res., October 1, 2003; 63(19): 6405 - 6412.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. R. Macpherson, S. S.W. Ng, S. L. Forbes, G. Melillo, T. Karpova, J. McNally, T. P. Conrads, T. D. Veenstra, A. Martinez, F. Cuttitta, et al.
Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay
Mol. Cancer Ther., September 1, 2003; 2(9): 845 - 854.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. T. Beck, N. Y. Chen, K. J. Franek, and W. Y. Chen
Prolactin Antagonist-endostatin Fusion Protein as a Targeted Dual-Functional Therapeutic Agent for Breast Cancer
Cancer Res., July 1, 2003; 63(13): 3598 - 3604.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Nyberg, P. Heikkila, T. Sorsa, J. Luostarinen, R. Heljasvaara, U.-H. Stenman, T. Pihlajaniemi, and T. Salo
Endostatin Inhibits Human Tongue Carcinoma Cell Invasion and Intravasation and Blocks the Activation of Matrix Metalloprotease-2, -9, and -13
J. Biol. Chem., June 13, 2003; 278(25): 22404 - 22411.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
A. Reijerkerk, L. O. Mosnier, O. Kranenburg, B. N. Bouma, P. Carmeliet, T. Drixler, J. C.M. Meijers, E. E. Voest, and M. F.B.G. Gebbink
Amyloid Endostatin Induces Endothelial Cell Detachment by Stimulation of the Plasminogen Activation System
Mol. Cancer Res., June 1, 2003; 1(8): 561 - 568.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Thomas, R. Z. Arzoomanian, D. Alberti, R. Marnocha, F. Lee, A. Friedl, K. Tutsch, A. Dresen, P. Geiger, J. Pluda, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
J. Clin. Oncol., January 15, 2003; 21(2): 223 - 231.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
N. Ortega and Z. Werb
New functional roles for non-collagenous domains of basement membrane collagens
J. Cell Sci., November 15, 2002; 115(22): 4201 - 4214.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Aharinejad, D. Abraham, P. Paulus, H. Abri, M. Hofmann, K. Grossschmidt, R. Schafer, E. R. Stanley, and R. Hofbauer
Colony-stimulating Factor-1 Antisense Treatment Suppresses Growth of Human Tumor Xenografts in Mice
Cancer Res., September 15, 2002; 62(18): 5317 - 5324.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Eder Jr, J. G. Supko, J. W. Clark, T. A. Puchalski, R. Garcia-Carbonero, D. P. Ryan, L. N. Shulman, J. Proper, M. Kirvan, B. Rattner, et al.
Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily
J. Clin. Oncol., September 15, 2002; 20(18): 3772 - 3784.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Herbst, N. A. Mullani, D. W. Davis, K. R. Hess, D. J. McConkey, C. Charnsangavej, M. S. O'Reilly, H.-W. Kim, C. Baker, J. Roach, et al.
Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin
J. Clin. Oncol., September 15, 2002; 20(18): 3804 - 3814.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. A. Scappaticci
Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-M. Kim, S. Hwang, Y.-M. Kim, B.-J. Pyun, T.-Y. Kim, S.-T. Lee, Y. S. Gho, and Y.-G. Kwon
Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1
J. Biol. Chem., July 26, 2002; 277(31): 27872 - 27879.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
D. R. Sorensen, T.-A. Read, T. Porwol, B. R. Olsen, R. Timpl, T. Sasaki, P. O. Iversen, H. B. Benestad, B. K. L. Sim, and R. Bjerkvig
Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma
Neuro-oncol, January 1, 2002; 4(1): 1 - 8.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Mundhenke, J. P. Thomas, G. Wilding, F. T. Lee, F. Kelzc, R. Chappell, R. Neider, L. A. Sebree, and A. Friedl
Tissue Examination to Monitor Antiangiogenic Therapy: A Phase I Clinical Trial with Endostatin
Clin. Cancer Res., November 1, 2001; 7(11): 3366 - 3374.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T.-A. Read, M. Farhadi, R. Bjerkvig, B. R. Olsen, A. M. Rokstad, P. C. Huszthy, and P. Vajkoczy
Intravital Microscopy Reveals Novel Antivascular and Antitumor Effects of Endostatin Delivered Locally by Alginate-encapsulated Cells
Cancer Res., September 1, 2001; 61(18): 6830 - 6837.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. S. Pepper
Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis
Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1104 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Folkman
Can mosaic tumor vessels facilitate molecular diagnosis of cancer?
PNAS, January 16, 2001; 98(2): 398 - 400.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
O. Musso, M. Rehn, N. Théret, B. Turlin, P. Bioulac-Sage, D. Lotrian, J.-P. Campion, T. Pihlajaniemi, and B. Clément
Tumor Progression Is Associated with a Significant Decrease in the Expression of the Endostatin Precursor Collagen XVIII in Human Hepatocellular Carcinomas
Cancer Res., January 1, 2001; 61(1): 45 - 49.
[Abstract] [Full Text]

Home page
 ASH Education BookHome page
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology, January 1, 2001; 2001(1): 443 - 462.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.